Collaboration to Bring Custom Flow Assay Design and Supply

A partnership between SYGNIS AG - under the ‘Innova’ Biosciences brand name has established a partnership with Abingdon Health Ltd, to provide its customers with full lateral flow assay development services, as well as establishing Innova as the preferred colloidal gold supplier to Abingdon.

The global market for lateral flow assays is growing at about 16% per annum and projected to be worth USD 8.2 billion by 2022, driven by the high prevalence of infectious diseases worldwide and the rising demand for point-of-care testing.The partnership opens up an exciting opportunity for both companies to reach this rapidly expanding market, predicted to reach USD39.96 billion by 2021. The collaboration will allow the SYGNIS Group access to Abingdon ADXLR5 reader systems, extending its custom lateral flow assay (LFA) services to include bulk manufacture.

Alastair Carrington, VP of Business Development & Marketing at Innova Biosciences, a SYGNIS company, commented: “There has been a long standing relationship between Abingdon and Innova. I am very pleased we are now able to set up a commercial partnership that brings together two innovative, industry leading organisations, with a clear complementary synergy to provide a total solution to the lateral flow community.”

Chris Yates, CEO of Abingdon Health, commented: “We are pleased to launch our collaboration with Innova. The provision of Innova’s bioconjugation expertise supports our strategy to provide a best-in-class lateral flow assay and reader development and manufacturing service to our contract customers.”